Cronos Group Inc. (CRON)
USD 1.66
(-3.22%)
USD 1.66
(-3.22%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.13 Billion USD | -6.49% |
| 2022 | 1.21 Billion USD | -13.22% |
| 2021 | 1.39 Billion USD | -27.42% |
| 2020 | 1.92 Billion USD | -7.88% |
| 2019 | 2.09 Billion CAD | 990.4% |
| 2018 | 191.71 Million CAD | 138.62% |
| 2017 | 80.34 Million CAD | 151.71% |
| 2016 | 31.91 Million CAD | 200.82% |
| 2015 | 10.61 Million CAD | 23.78% |
| 2014 | 8.57 Million CAD | 565.74% |
| 2013 | 1.28 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.09 Billion USD | -1.49% |
| 2024 Q1 | 1.1 Billion USD | -2.37% |
| 2023 Q4 | 1.13 Billion USD | -1.38% |
| 2023 FY | 1.13 Billion USD | -6.49% |
| 2023 Q1 | 1.15 Billion USD | -4.41% |
| 2023 Q2 | 1.16 Billion USD | 0.76% |
| 2023 Q3 | 1.15 Billion USD | -1.56% |
| 2022 Q2 | 1.33 Billion USD | -2.83% |
| 2022 Q3 | 1.23 Billion USD | -7.11% |
| 2022 Q1 | 1.37 Billion USD | -1.91% |
| 2022 FY | 1.21 Billion USD | -13.22% |
| 2022 Q4 | 1.21 Billion USD | -1.98% |
| 2021 Q1 | 1.88 Billion USD | -2.31% |
| 2021 Q4 | 1.39 Billion USD | -8.95% |
| 2021 Q3 | 1.53 Billion USD | -16.5% |
| 2021 FY | 1.39 Billion USD | -27.42% |
| 2021 Q2 | 1.83 Billion USD | -2.27% |
| 2020 Q1 | 1.92 Billion USD | -7.77% |
| 2020 Q2 | 1.91 Billion USD | -0.91% |
| 2020 Q4 | 1.92 Billion USD | 0.35% |
| 2020 FY | 1.92 Billion USD | -7.88% |
| 2020 Q3 | 1.91 Billion USD | 0.45% |
| 2019 Q2 | 2.03 Billion CAD | 0.56% |
| 2019 Q4 | 2.09 Billion CAD | 0.17% |
| 2019 Q3 | 2.08 Billion CAD | 2.71% |
| 2019 FY | 2.09 Billion CAD | 990.4% |
| 2019 Q1 | 2.02 Billion CAD | 954.02% |
| 2018 Q1 | 108.59 Million CAD | 35.17% |
| 2018 Q3 | 181.46 Million CAD | 1.37% |
| 2018 Q4 | 191.71 Million CAD | 5.65% |
| 2018 FY | 191.71 Million CAD | 138.62% |
| 2018 Q2 | 179.01 Million CAD | 64.85% |
| 2017 Q3 | 64.01 Million CAD | 51.11% |
| 2017 Q4 | 80.34 Million CAD | 25.5% |
| 2017 FY | 80.34 Million CAD | 151.71% |
| 2017 Q2 | 42.36 Million CAD | -3.6% |
| 2017 Q1 | 43.94 Million CAD | 37.69% |
| 2016 Q2 | 12.13 Million CAD | 13.54% |
| 2016 FY | 31.91 Million CAD | 200.82% |
| 2016 Q1 | 10.68 Million CAD | 0.73% |
| 2016 Q4 | 31.91 Million CAD | 5.94% |
| 2016 Q3 | 30.12 Million CAD | 148.26% |
| 2015 Q2 | 8.07 Million CAD | 8.85% |
| 2015 FY | 10.61 Million CAD | 23.78% |
| 2015 Q3 | 7.09 Million CAD | -12.21% |
| 2015 Q4 | 10.61 Million CAD | 49.63% |
| 2015 Q1 | 7.41 Million CAD | 0.0% |
| 2014 Q2 | 234.76 Thousand CAD | 0.0% |
| 2014 Q3 | 661.26 Thousand CAD | 181.68% |
| 2014 FY | 8.57 Million CAD | 565.74% |
| 2013 FY | 1.28 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | -1610.902% |
| Safety Shot Inc | 12.7 Million USD | -8824.667% |
| Bright Green Corporation | 17.4 Million USD | -6417.548% |
| Embecta Corp. | 1.21 Billion USD | 6.6% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | -25.412% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -1875.429% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 0.792% |
| Dynavax Technologies Corporation | 997.09 Million USD | -13.756% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -451.154% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -55.741% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 27.956% |
| PainReform Ltd. | 9.93 Million USD | -11322.477% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -4047.634% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -4047.634% |
| SCYNEXIS, Inc. | 128.41 Million USD | -783.291% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -4804.437% |
| Journey Medical Corporation | 76.84 Million USD | -1375.949% |
| Alpha Teknova, Inc. | 128.58 Million USD | -782.089% |
| Procaps Group, S.A. | 460.18 Million USD | -146.476% |
| Theratechnologies Inc. | 77.76 Million USD | -1358.489% |
| Harrow Health, Inc. | 311.75 Million USD | -263.828% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -7516.007% |
| Biofrontera Inc. | 27.93 Million USD | -3960.762% |
| DURECT Corporation | 45.18 Million USD | -2410.018% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 19.498% |
| OptiNose, Inc. | 107.72 Million USD | -952.875% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -140.781% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1927.296% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -4821.444% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -146.563% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -9416.992% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -1287.022% |
| Radius Health, Inc. | 1.71 Billion USD | 33.899% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -2028.57% |
| ProPhase Labs, Inc. | 91.92 Million USD | -1133.862% |
| Phibro Animal Health Corporation | 982.18 Million USD | -15.483% |
| Procaps Group S.A. | 460.18 Million USD | -146.476% |
| Alvotech | 950.09 Million USD | -19.384% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -2518.975% |
| Viatris Inc. | 47.68 Billion USD | 97.621% |
| Rockwell Medical, Inc. | 52.17 Million USD | -2074.021% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -860.457% |
| SIGA Technologies, Inc. | 254.83 Million USD | -345.091% |
| Tilray Brands, Inc. | 4.33 Billion USD | 73.837% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -314.411% |
| Shineco, Inc. | 84.17 Million USD | -1247.423% |
| PetIQ, Inc. | 868.22 Million USD | -30.64% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -13341.854% |
| Incannex Healthcare Limited | 17.04 Million USD | -6553.675% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 65.115% |
| Alimera Sciences, Inc. | 153.52 Million USD | -638.811% |
| Silver Spike Investment Corp. | 88.57 Million USD | -1180.537% |
| Assertio Holdings, Inc. | 286.41 Million USD | -296.011% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -18957.498% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -3256.193% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -3530.42% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -8461.983% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -334.37% |
| Hempacco Co., Inc. | 18.04 Million USD | -6186.355% |
| Talphera, Inc. | 20.39 Million USD | -5461.422% |
| Alvotech | 950.09 Million USD | -19.384% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -179.262% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 31.305% |
| Currenc Group, Inc. | 141.49 Million USD | -701.646% |
| Kamada Ltd. | 351.96 Million USD | -222.258% |
| Indivior PLC | 1.95 Billion USD | 41.87% |
| Evoke Pharma, Inc. | 7.06 Million USD | -15946.468% |
| Flora Growth Corp. | 23.62 Million USD | -4700.863% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -8461.983% |
| Evolus, Inc. | 188.99 Million USD | -500.14% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 11.371% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 25.029% |
| Akanda Corp. | 8.83 Million USD | -12730.915% |